Study #2023-0709
ADI-PEG 20 or Placebo plus Gemcitabine and Docetaxel in previously treated subjects with Leiomyosarcoma (ARGSARC): A randomized, double blind, multi-Center phase 3 trial
MD Anderson Study Status
Enrolling
Treatment Agent
ADI PEG20
Description
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Soft Tissue Sarcoma
Study phase:
Phase III
Physician name:
John Livingston
Department:
Sarcoma Medical Oncology
For general questions about clinical trials:
1-855-479-2433
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.